A statistically significant improvement in PFS as determined by the IRC was demonstrated for patients randomized to Afatinib compared with those randomized to chemotherapy. See Table 5 and Figure 1. There was no statistically significant difference for OS between the treatment arms at the final pre-planned analysis.
from FDA,2022.04